Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA172845 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Human Breast Cancer Cell Lines: Control vs. Fn14 or Luciferase siRNA Treated
| PRJNA102239 | ENA
Project description:Human Prostate Cancer Cells: ISL-treated cells vs. Control
| PRJNA395047 | ENA
Project description:Human MCF-7 breast cancer cells: control vs. treated with conditioned medium of cancer associated adipose tissue
| PRJNA252929 | ENA
Project description:Human Breast Cancer Cell MCF-7: Control vs. Gli1 Transfected
| PRJNA232729 | ENA
Project description:Human breast cancer LM2 cell lines: control vs. MTDH knockdown
| PRJNA102757 | ENA
Project description:Human Renal Cancer Cells: Control vs STF-62247-treated cells
| PRJNA339764 | ENA
Project description:To investigate the significant differently expressed genes upon the stimulation of breast cancer patients' sera. Cells were untreated or treated with 10% breast cancer patients' sera for 24h followed by isolation of total RNA using TRIZOL. Gene-expression profiling was performed on the CapitalBio 35k human Genome Array microchips (Beijing, China).
2012-08-14 | E-GEOD-40108 | biostudies-arrayexpress
Project description:Transcriptional profiling of Homo sapiens inflammatory skin diseases (whole skin biospies): Psoriasis (Pso), vs Atopic Dermatitis (AD) vs Lichen planus (Li), vs Contact Eczema (KE), vs Healthy control (KO) In recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of the most common inflammatory skin diseases worldwide. However, most of these markers are not psoriasis-specific but also found in other inflammatory disorders. We performed an unsupervised cluster analysis of gene expression profiles in 150 psoriasis patients and other inflammatory skin diseases (atopic dermatitis, lichen planus, contact eczema, and healthy controls). We identified a cluster of IL-17/TNFα-associated genes specifically expressed in psoriasis, among which IL-36γ was the most outstanding marker. In subsequent immunohistological analyses IL-36γ was confirmed to be expressed in psoriasis lesions only. IL-36γ peripheral blood serum levels were found to be closely associated with disease activity, and they decreased after anti-TNFα-treatment. Furthermore, IL-36γ immunohistochemistry was found to be a helpful marker in the histological differential diagnosis between psoriasis and eczema in diagnostically challenging cases. These features highlight IL-36γ as a valuable biomarker in psoriasis patients, both for diagnostic purposes and measurement of disease activity during the clinical course. Furthermore, IL-36γ might also provide a future drug target, due to its potential amplifier role in TNFα- and IL-17 pathways in psoriatic skin inflammation. In recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of the most common inflammatory skin diseases worldwide. However, most of these markers are not psoriasis-specific but also found in other inflammatory disorders. We performed an unsupervised cluster analysis of gene expression profiles in 150 psoriasis patients and other inflammatory skin diseases (atopic dermatitis, lichen planus, contact eczema, and healthy controls). We identified a cluster of IL-17/TNFα-associated genes specifically expressed in psoriasis, among which IL-36γ was the most outstanding marker. In subsequent immunohistological analyses IL-36γ was confirmed to be expressed in psoriasis lesions only. IL-36γ peripheral blood serum levels were found to be closely associated with disease activity, and they decreased after anti-TNFα-treatment. Furthermore, IL-36γ immunohistochemistry was found to be a helpful marker in the histological differential diagnosis between psoriasis and eczema in diagnostically challenging cases. These features highlight IL-36γ as a valuable biomarker in psoriasis patients, both for diagnostic purposes and measurement of disease activity during the clinical course. Furthermore, IL-36γ might also provide a future drug target, due to its potential amplifier role in TNFα- and IL-17 pathways in psoriatic skin inflammation.
2014-12-02 | GSE63741 | GEO
Project description:Human Breast Cancer cells: Control vs Treated with Palbociclib
| PRJNA563027 | ENA
Project description:Human Non-Small Cell Lung Cancer cells: Control vs gefitinib treated cells
| PRJNA406984 | ENA